StockpollyBeta
Get App
Popularity #288
ZTS · NYSE · Drug Manufacturers - Specialty & Generic

Zoetis (ZTS)

Develops medicines, vaccines, diagnostics and precision-health tools for pets and livestock.

$71.71
vs last close−1.19 (−1.63%)
Loading prices…

Something off on this page? Send us feedback.

Zoetis Inc.ZTS
Health Care

Develops and sells medicines, vaccines, diagnostics, genetic tests and precision-health tools for companion animals and livestock. Most revenue comes from companion-animal products, with sales organized across U.S. and International segments and a small group of parasiticide, dermatology and pain franchises accounting for a large share.

Develops, manufactures and sells animal medicines, vaccines, diagnostics, genetic tests and precision-health tools for pets and livestock. The portfolio spans parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals and animal health diagnostics. Companion-animal products generate most revenue, anchored by Simparica and Simparica Trio, Apoquel, Cytopoint and Librela, while livestock offerings include vaccines and ceftiofur antibiotics.

Operates through U.S. and International commercial segments, selling in more than 100 countries through direct veterinary and livestock-producer relationships plus distributors. Combines veterinary R&D, global manufacturing, technical sales and lifecycle development across its portfolio. Results depend on regulatory approvals, product safety and quality, reliable supply, veterinary visits and livestock conditions; a small group of top products and product lines generates roughly two-fifths of revenue.

Company facts

CEOKristin C. Peck
ListedFeb 1, 2013
ExchangeNYSE
HeadquartersParsippany, NJ
CountryUnited States
Employees14,500
CIK0001555280
ISINUS98978V1035

Market cap$30.56B
EPS (ttm)$6.07
P/E (ttm)12.01
ROE69.3%
P/B9.71
P/S3.21
Dividend yieldDiv yield2.87%
Beta0.57vs XLV 0.77

Price target$85.00+16.6%Average of 32 analysts
ConsensusHold17 of 32 analysts
Ratings

Target rangeAs of Sep 22, 2026

Latest analyst notes

DateFirmActionPriorCurrent
Aug 25, 2026Cantor FitzgeraldTarget
Target: —
Target: $94
Aug 20, 2026Stifel NicolausTarget
Target: $85
Target: $80
Aug 7, 2026Morgan StanleyTarget
Target: $99
Target: $85
Aug 6, 2026William BlairDowngrade
Rating: Outperform
Rating: Market Perform
Jul 27, 2026UBSReiterate
Rating: —Target: $99
Rating: NeutralTarget: $85

Next report
Nov 3, 26
in 41 days
EPS estimate
$1.52
Revenue estimate
$2.29B
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$1.40$1.48$1.76$1.70$1.48$1.53$1.87Pending
Estimate$1.37$1.41$1.62$1.62$1.40$1.60$1.85$1.52
Surprise+2.2%+5.0%+8.6%+4.9%+5.7%−4.4%+1.1%—

RevenueReportedEstimate

Feb '25May '25Aug '25Nov '25Feb '26May '26Aug '26Nov '26
Reported$2.32B$2.22B$2.46B$2.40B$2.39B$2.26B$2.47BPending
Estimate$2.30B$2.19B$2.41B$2.41B$2.36B$2.30B$2.50B$2.29B
Surprise+0.9%+1.4%+2.1%−0.4%+1.1%−1.7%−1.3%—
Estimate$1.52
ReportedDue Nov 3, 2026
Estimate$2.29B
ReportedDue Nov 3, 2026
View details

Debt to equity293.50%
Current ratio308.40%

ProfitabilityRevenueNet incomeNet margin

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Revenue$2.39B$2.32B$2.22B$2.46B$2.40B$2.39B$2.26B$2.47B
Net income$682.0M$581.0M$631.0M$718.0M$721.0M$603.0M$601.0M$691.0M
Net margin28.6%25.1%28.4%29.2%30.0%25.3%26.6%28.0%

GrowthOperating income

Q3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26
Operating income$920.0M$765.0M$846.0M$989.0M$936.0M$826.0M$822.0M$937.0M
YoY growth+15.3%+7.9%+5.6%+9.2%+1.7%+8.0%−2.8%−5.3%

Balance sheet, Jun 30, 2026Cash & short-term investments $1.68B · Total debt $9.24B · Total assets $15.08B · Shareholders' equity $3.15B

Revenue
$2.47B
Operating income
$937.0M
Net income
$691.0M
View details

Dividend yield
2.87%
Next ex-date
Oct 20, 26
estimated · in 27 days
Annual dividend
$2.09
per share
Schedule
Quarterly
4 payments a year

HistoryDividendAnnual yield

Oct '24Jan '25Apr '25Jul '25Oct '25Jan '26Apr '26Jul '26
Dividend$0.432$0.50$0.50$0.50$0.50$0.53$0.53$0.53
Annual yield0.97%1.07%1.27%1.30%1.39%1.65%1.68%2.74%
Ex-dateOct 31Jan 21Apr 21Jul 18Oct 31Jan 20Apr 20Jul 20
Payment dateDec 3Mar 4Jun 3Sep 3Dec 2Mar 3Jun 2Sep 1
View details

Institutions97.10%401.26M shares
1,491 holders · as of Jun 30, 2026
Insiders0.07%309.6K shares
21 holders · as of Aug 11, 2026
Strategic holders9.76%40.32M shares
1 holder · as of Feb 3, 2022
Adds to106.93%

413.22M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing

These groups come from separate filings that can overlap, so they add to 106.93%; nothing is left for Other.

Top shareholders13F · 13D/G · Form 4

HolderStakeSharesDate
BlackRock, Inc.Strategic
9.76%40.32Mfiled Feb 3, 2022
BlackRock, Inc.Institution
9.54%39.43Mas of Jun 30, 2026
Vanguard Capital Management LLCInstitution
6.30%26.03Mas of Jun 30, 2026
Vanguard Portfolio Management LLCInstitution
5.77%23.86Mas of Jun 30, 2026
State Street CorpInstitution
4.76%19.67Mas of Jun 30, 2026

Insider tradesForm 4

DateInsiderRoleSharesAvg price
May 13, 2026Paul Bisarodirector+2,000$75.88
May 13, 2026Frank A. Dameliodirector+6,650$75.39
May 11, 2026Michael B. Mccallisterdirector+3,000$77.76
Feb 17, 2026Kristin C. Peckdirector, officer: Chief Executive Officer−20,000$127.05
View details

  • Merck

    Second-largest animal health business globally; Bravecto leads parasiticides.

  • Elanco Animal Health

    Full-portfolio rival in parasiticides, dermatology, pain, and vaccines.

  • IDEXX Laboratories

    Vet diagnostics leader; in-clinic analyzers and reference labs vs Zoetis.

  • Phibro Animal Health

    Acquired Zoetis MFA portfolio (400M rev) to become a feed additive rival.

Compare

CompanyPriceChange
Zoetis$71.71−1.63%$30.56B12.011.63.2+0.3%
Merck$147.63−2.18%$372.73B120.717.15.6+5.1%
Elanco Animal Health$22.64−1.25%$11.45B—19.02.3+10.2%
IDEXX Laboratories$518.60−0.56%$41.14B36.933.39.0+9.7%
Phibro Animal Health$34.29−2.46%$1.42B14.49.80.9+4.8%
Median36.918.13.9+7.4%